EGFR Chimeric Monoclonal Antibody

<strong>EGFR Chimeric Monoclonal Antibody </strong>_x000D_ <strong>Catalog number:</strong> B2017748_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 100 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Epidermal Growth Factor Receptor, ErbB-1, HER1_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W. Biological drug and drug delivery-mediated immunotherapy Acta Pharm Sin B. 2021 Apr;11(4):941-960._x000D_ 2: Mazzarella L, Guida A, Curigliano G. Cetuximab for treating non-small cell lung cancer Expert Opin Biol Ther. 2018 Apr;18(4):483-493._x000D_ 3: Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. Role of Fcγ receptors in HER2-targeted breast cancer therapy J Immunother Cancer. 2022 Jan;10(1):e003171._x000D_ 4: Wingert S, Reusch U, Knackmuss S, Kluge M, Damrat M, Pahl J, Schniegler-Mattox U, Mueller T, Fucek I, Ellwanger K, Tesar M, Haneke T, Koch J, Treder M, Fischer W, Rajkovic E. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors MAbs. 2021 Jan-Dec;13(1):1950264._x000D_ 5: Wollina U, Tchernev G, Lotti T. Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer Open Access Maced J Med Sci. 2017 Dec 31;6(1):152-155._x000D_ 6: Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9._x000D_ 7: Li G, Ohishi T, Kaneko MK, Takei J, Mizuno T, Kawada M, Saito M, Suzuki H, Kato Y. Defucosylated Mouse-Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors Cells. 2021 Dec 20;10(12):3599._x000D_ 8: Leung K. 4-[(18)F]Fluorobenzoyl-Phe-Ala-Leu-Gly-Glu-Ala-NH(2) 2011 Aug 26 [updated 2011 Dec 8]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013._x000D_ 9: Sommaggio R, Cappuzzello E, Dalla Pietà A, Tosi A, Palmerini P, Carpanese D, Nicolè L, Rosato A. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells Oncoimmunology. 2020 Jun 11;9(1):1777046._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/23300028">10: Pirker R. EGFR-directed monoclonal antibodies in non-small cell lung cancer Target Oncol. 2013 Mar;8(1):47-53. </a>_x000D_ _x000D_ <strong>Products Related to EGFR Chimeric Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>